Furthermore, expression of YTHDC1, especially its alternative splicing components, was detected in a panel of prostate cell lines that was absent in benign cell lines, indicating that YTHDC1 might act as an oncogene in prostate cancer [31]. Here, YTHDC1 is linked to prostate carcinoma.